The Safety of Simvastatin (SOS) in Patients With Pulmonary Lymphangioleiomyomatosis (LAM) and With Tuberous Sclerosis Complex (TSC)

Trial Profile

The Safety of Simvastatin (SOS) in Patients With Pulmonary Lymphangioleiomyomatosis (LAM) and With Tuberous Sclerosis Complex (TSC)

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 19 Jun 2017

At a glance

  • Drugs Simvastatin (Primary)
  • Indications Lymphangioleiomyomatosis; Tuberous sclerosis
  • Focus Adverse reactions
  • Acronyms SOS
  • Most Recent Events

    • 12 Jun 2017 Planned End Date changed from 1 Dec 2017 to 1 Jan 2018.
    • 12 Jun 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Jan 2018.
    • 04 Dec 2015 Planned End Date changed from 1 Jun 2016 to 1 Dec 2017, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top